Paper Proffered Program Radiopharmaceuticals, Theranostics, and Nuclear Medicine

Improving Glucose Metabolic Rate Estimates without Arterial Blood Sampling

Abstract
Purpose

Two key challenges in pharmacokinetic modeling (PKM) of dynamic PET are metabolite contamination of the image-derived arterial input function (AIF) and the presence of these metabolites in tissue time-activity curves (TACs). We propose a method to correct for both issues without arterial blood sampling, using brain [18F]-FDG studies as an example, where the metabolite is [18F]-FDG trapped in red blood cells (RBCs).

Methods

Five dynamic FDG-PET brain scans from four patients were analyzed. High-resolution images were reconstructed using QClear (GE Healthcare) to minimize partial volume effects. AIFs were averaged from maximal points in 10-15 slices of the extracranial internal carotid artery. The approach used iterative simultaneous estimation (SIME), fitting four brain TACs with different kinetics and a corrected AIF. Our critical modification to the original SIME framework, which enables convergence, was to iteratively define the difference between the measured and fitted AIF as the RBC AIF and subtract its estimated contribution from the tissue TACs. At convergence, the image-derived AIF is successfully decomposed into the corrected plasma AIF and the RBC AIF.

Results

The algorithm converged using only image-derived data. Patlak graphical analysis with the corrected plasma AIF produced a glucose metabolic rate (MRglu) of 41.6 ± 14.6 µmol/min/100g, compared to 24.7 ± 7.7 µmol/min/100g using the uncorrected AIF. These MRglu estimates align with literature values but reveal a potential 1.7-fold underestimation when using the uncorrected, RBC-contaminated input function.

Conclusion

Our study demonstrates that a modified SIME (mSIME) method can estimate a metabolite-corrected plasma AIF without arterial blood sampling. This correction significantly impacts PKM, potentially improving the quantitative accuracy of MRglu estimates by addressing RBC contamination. Future work will involve validation using large animals with arterial blood sampling.

People

Related

Similar sessions

Poster Poster Program
Jul 19 · 07:00
Adverse Events in Targeted Radionuclide Therapy

Radiopharmaceutical therapy (RPT) plays an important role in the management of oncology patients, particularly those with thyroid cancer, prostate cancer, and neuroendocrine tumor. The use of radionuclide therapy has expanded rap...

Harrison L. Agordzo
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Development of a Web-Based Theranostic Workflow Management Tool

To develop a Web-Based Theranostic Workflow Management Tool (TWMT) to efficiently manage Theranostic program in the department of radiation oncology (RadOnc).

Ling Zhuang, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Epidseg-Net:the Multi-Modal Fusion Framework Based on Drr Guidance In Radiotherapy Is Used for Precise Segmentation of Epid Lung Targets

The proposed multimodal segmentation framework, named EPIDSeg-Net, comprises an encoder, a multi-scale feature layer, and a decoder. The encoder utilizes a dual-branch architecture: a CNN branch for extracting local texture featu...

Huang Qian Qianjia, M.Eng
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested